Last reviewed · How we verify
Januvia Tab. 100mg
At a glance
| Generic name | Januvia Tab. 100mg |
|---|---|
| Also known as | Sitagliptin 100mg |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Any Infections And Infestations
- Any Gastrointestinal disorders
- Diarrhoea
- Hypoglycemia
- abdominal distension and abdominal pain 8 cases, dizziness 2 cases, constipation 2 cases
- Nasopharyngitis
- Upper Respiratory Tract Infection
- Any Gastrointestinal Disorders
- Any General Disorders And Administration Site Conditions
- Oedema Peripheral
- Any Musculoskeletal And Connective Tissue Disorders
- Back Pain
Key clinical trials
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Effects of Sitagliptin in Individuals With Genetically Decreased DPP4 (PHASE4)
- iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) (PHASE3)
- Canagliflozin and Myocardial Fibrosis (PHASE4)
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes (PHASE4)
- Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients (PHASE3)
- DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes (PHASE4)
- Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Januvia Tab. 100mg CI brief — competitive landscape report
- Januvia Tab. 100mg updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI